Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2026-03-06 @ 2:55 PM
Study NCT ID:
NCT05405660
Status:
COMPLETED
Last Update Posted:
2025-11-06
First Post:
2022-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000094482', 'term': 'Chronic Inducible Urticaria'}], 'ancestors': [{'id': 'D000080223', 'term': 'Chronic Urticaria'}, {'id': 'D014581', 'term': 'Urticaria'}, {'id': 'D017445', 'term': 'Skin Diseases, Vascular'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 196}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-06-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'dispFirstSubmitDate': '2025-06-10', 'completionDateStruct': {'date': '2025-09-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-04', 'studyFirstSubmitDate': '2022-06-01', 'studyFirstSubmitQcDate': '2022-06-01', 'dispFirstPostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2025-11-06', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-06-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of patients with a negative provocation test at week 12', 'timeFrame': 'From baseline to week 12', 'description': 'Percentage of patients with a negative provocation test for Cold Inducible Urticaria \\[ColdU\\] or Symptomatic Dermographism \\[SD\\]) at week 12\n\n* For ColdU patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at ≤ 4°C after provocation using TempTest®\n* For SD patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at 0 pins after provocation using the FricTest®'}], 'secondaryOutcomes': [{'measure': 'Change in provocation threshold and itch for ColdU', 'timeFrame': 'From baseline to week 12', 'description': 'Mean change from baseline to week 12 in critical temperature threshold (CTT) in patients with ColdU\n\nCTT is defined as threshold temperature at which wheals are triggered (highest temperature for cold), assessed at the 10-minute mark'}, {'measure': 'Change in provocation threshold for SD', 'timeFrame': 'From baseline to week 12', 'description': 'Mean change from baseline to Week 12 in Critical Friction Threshold (CFT) in patients with SD\n\nCFT is the threshold pin number at which wheals are triggered, assessed at the 10-minute mark'}, {'measure': 'Change in worst itch reported after provocation for ColdU', 'timeFrame': 'From baseline to week 12', 'description': 'Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with ColdU'}, {'measure': 'Combined patients with a negative provocation test at week 12', 'timeFrame': 'From baseline to week 12', 'description': 'Percentage of combined patients with a negative TempTest (ColdU) or FricTest (SD) at week 12'}, {'measure': 'Change in worst itch reported after provocation for SD', 'timeFrame': 'From baseline to week 12', 'description': 'Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD'}, {'measure': 'Change in worst itch reported after provocation in both SD and ColdU', 'timeFrame': 'From baseline to week 12', 'description': 'Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD and ColdU combined'}, {'measure': 'Percentage of patients experiencing adverse events', 'timeFrame': 'From baseline to week 20', 'description': 'Percentage of patients experiencing treatment-emergent adverse events (TEAE) examined by ColdU patients, SD patients and in combination. A TEAE is any untoward medical occurrence in a patient administered a study treatment.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CDX-0159', 'barzolvolimab'], 'conditions': ['Chronic Inducible Urticaria']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.', 'detailedDescription': 'The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Inducible Urticaria (Cold Urticaria \\[ColdU\\] or Symptomatic Dermographism \\[SD\\]) who remain symptomatic despite the use of H1-antihistamines.\n\nThere is a screening period of up to 4 weeks, followed by a 20-week treatment period where patients will receive either barzolvolimab 150mg, 300mg or placebo, and then a 24-week follow up period where all patients are observed.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key inclusion criteria:\n\n1. Males and females, \\>/= 18 years of age.\n2. Diagnosis of chronic ColdU or SD \\>/= 3 months.\n3. Diagnosis of ColdU or SD despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:\n\n 1. Recurrent pruritic wheals with or without angioedema due to ColdU or SD for \\>/= 6 weeks at any time prior to Visit 1 despite the use of H1-antihistamines.\n 2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for \\>/= 4 weeks prior to study treatment and agree to stay on through trial.\n 3. UCT \\< 12 during the 14 days prior to treatment.\n4. Positive provocation test\n\n 1. for ColdU patients: developing a wheal at the test site within 10 min after using TempTest® at any temperature at both screening (Visit 1) and randomization (Visit 3)\n 2. for SD patients: developing a wheal at the test site within 10 min after using FricTest® with ≥ 3 pins at both screening (Visit 1) and randomization (Visit 3)\n5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.\n6. Willing and able to complete a daily symptom electronic diary and comply with study visits.\n\nKey exclusion criteria:\n\n1. Women who are pregnant or nursing.\n2. Active Chronic spontaneous urticaria or other forms of CIndU besides ColdU or SD that may interfere with study assessments.\n3. Active, pruritic skin condition in addition to CIndU.\n4. Medical condition that would cause additional risk or interfere with study procedures.\n5. Known active HIV, hepatitis B or hepatitis C infection.\n6. Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.\n7. History of anaphylaxis\n\nThere are additional criteria that your study doctor will review with you to confirm you are eligible for the study.'}, 'identificationModule': {'nctId': 'NCT05405660', 'briefTitle': 'A Study of CDX-0159 in Patients With Chronic Inducible Urticaria', 'organization': {'class': 'INDUSTRY', 'fullName': 'Celldex Therapeutics'}, 'officialTitle': ': A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria', 'orgStudyIdInfo': {'id': 'CDX0159-07'}, 'secondaryIdInfos': [{'id': '2021-006447-95', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'barzolvolimab 150 mg in patients with Symptomatic Dermographism', 'description': 'barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks', 'interventionNames': ['Biological: barzolvolimab']}, {'type': 'EXPERIMENTAL', 'label': 'barzolvolimab 300 mg in patients with Symptomatic Dermographism', 'description': 'barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks', 'interventionNames': ['Biological: barzolvolimab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Comparator in patients with Symptomatic Dermographism', 'description': 'Placebo injection subcutaneous every 4 weeks for 20 weeks', 'interventionNames': ['Drug: Matching Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria', 'description': 'barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks', 'interventionNames': ['Biological: barzolvolimab']}, {'type': 'EXPERIMENTAL', 'label': 'barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria', 'description': 'barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks', 'interventionNames': ['Biological: barzolvolimab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Comparator in patients with Chronic Inducible Cold Urticaria', 'description': 'Placebo injection subcutaneous every 4 weeks for 20 weeks', 'interventionNames': ['Drug: Matching Placebo']}], 'interventions': [{'name': 'barzolvolimab', 'type': 'BIOLOGICAL', 'otherNames': ['CDX-0159'], 'description': 'Subcutaneous Administration', 'armGroupLabels': ['barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria', 'barzolvolimab 150 mg in patients with Symptomatic Dermographism', 'barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria', 'barzolvolimab 300 mg in patients with Symptomatic Dermographism']}, {'name': 'Matching Placebo', 'type': 'DRUG', 'description': 'Subcutaneous Administration', 'armGroupLabels': ['Placebo Comparator in patients with Chronic Inducible Cold Urticaria', 'Placebo Comparator in patients with Symptomatic Dermographism']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35249', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Clinical Research Center of Alabama', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '36106', 'city': 'Montgomery', 'state': 'Alabama', 'country': 'United States', 'facility': 'Allervie Clinical Research', 'geoPoint': {'lat': 32.36681, 'lon': -86.29997}}, {'zip': '85253', 'city': 'Paradise Valley', 'state': 'Arizona', 'country': 'United States', 'facility': 'One of a Kind Clinical Research Center, LLC', 'geoPoint': {'lat': 33.53115, 'lon': -111.94265}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Little Rock Allergy & Asthma CRC', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '93301', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'Kern Research, Inc', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '94063', 'city': 'Redwood City', 'state': 'California', 'country': 'United States', 'facility': 'Allergy & Asthma Consultants', 'geoPoint': {'lat': 37.48522, 'lon': -122.23635}}, {'zip': '80112', 'city': 'Centennial', 'state': 'Colorado', 'country': 'United States', 'facility': 'IMMUNOe Research Centers', 'geoPoint': {'lat': 39.57916, 'lon': -104.87692}}, {'zip': '34239', 'city': 'Sarasota', 'state': 'Florida', 'country': 'United States', 'facility': 'Sarasota Clinical Research', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'zip': '83706', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Treasure Valley Medical Research', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '46250', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Dawes Fretzin Dermatology Group, LLC', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '42301', 'city': 'Owensboro', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Allergy & Asthma Specialists, PSC', 'geoPoint': {'lat': 37.77422, 'lon': -87.11333}}, {'zip': '20815', 'city': 'Chevy Chase', 'state': 'Maryland', 'country': 'United States', 'facility': 'Institute for Asthma and Allergy, PC/Department of Clinical Research', 'geoPoint': {'lat': 39.00287, 'lon': -77.07115}}, {'zip': '48197', 'city': 'Ypsilanti', 'state': 'Michigan', 'country': 'United States', 'facility': 'Respiratory Medicine Research Institute of Michigan, PLC', 'geoPoint': {'lat': 42.24115, 'lon': -83.61299}}, {'zip': '45267', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'University of Cincinnati', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '78028', 'city': 'Kerrville', 'state': 'Texas', 'country': 'United States', 'facility': 'Allergy Partners of Kerrville', 'geoPoint': {'lat': 30.04743, 'lon': -99.14032}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'country': 'United States', 'facility': 'Allergy Associates of Utah', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '7200', 'city': 'Razgrad', 'country': 'Bulgaria', 'facility': 'Outpatient Clinic for Individual Practice for Specialized Outpatient', 'geoPoint': {'lat': 43.53331, 'lon': 26.51849}}, {'zip': '1504', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Medical Center Iskar- EOOD Office of Clinical Allergology', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '"Medical Center Ekselsior" OOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '"University Multiprofile Hospital for Active Treatment \'Aleksandrovska" EAD, Clinic of Clinical Allergology', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Medical Center "SYNEXUS SOFIA", EOOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Stara Zagora', 'country': 'Bulgaria', 'facility': 'University Multiprofile Hospital for Active Treatment "Prof. Dr. Stoyan Kirkovich" AD', 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'zip': '10134', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Vahlberg & Pild Clinic', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '11312', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'East Tallin Central Hospital', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '6000', 'city': 'Batumi', 'country': 'Georgia', 'facility': 'High Technology Hospital Medcenter', 'geoPoint': {'lat': 41.64077, 'lon': 41.6306}}, {'zip': '0119', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Healthy Future', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0159', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Center of Allergy and Immunology', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0186', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Multiprofile Clinic Consilium Medulla', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '86179', 'city': 'Augsburg', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'Universitätsklinikum Augsburg', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '80337', 'city': 'München', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'LMU Klinikum - Klinik und Poliklinik für Dermatologie und Allergologie DASZ-Dermato-Allergologisches Studien Zentrum', 'geoPoint': {'lat': 48.69668, 'lon': 13.46314}}, {'zip': '35043', 'city': 'Marburg', 'state': 'Hesse', 'country': 'Germany', 'facility': 'Universitaetsklinikum Giessen u. Marburg GmbH', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': '21614', 'city': 'Buxtehude', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Elbe Klinikum Buxtehude', 'geoPoint': {'lat': 53.46994, 'lon': 9.68968}}, {'zip': '30625', 'city': 'Hanover', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Hannover Medical University', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '26133', 'city': 'Oldenburg', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Klinikum Oldenburg gGmbH - Klinik f. Dermatologie u. Allergologie', 'geoPoint': {'lat': 53.14039, 'lon': 8.21479}}, {'zip': '40225', 'city': 'Düsseldorf', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Universitätsklinikum Düsseldorf - Dermatologie', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '45122', 'city': 'Essen', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Universitätsklinikum Essen Klinikum f. Dermatologie, Venerologie u. Allergologie Hufelandstr', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '48149', 'city': 'Münster', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Universitätsklinikum Münster Klinik u. Poliklinik f. Dermatologie', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '01307', 'city': 'Dresden', 'state': 'Saxony', 'country': 'Germany', 'facility': 'Universitätsklinikum Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '24105', 'city': 'Kiel', 'state': 'Schleswig-Holstein', 'country': 'Germany', 'facility': 'Universitätsklinikum Schleswig-Holstein - Zentrum für entzündliche Hauterkrankungen', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '12203', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Institute of Allergology IFA', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Universitätsklinikum Heidelberg - Dermatologie', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '1085', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'city': 'Budapest', 'country': 'Hungary', 'facility': 'Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': 'H-4032', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Debreceni Egyetem Klinikai Központ (DEKK), Bőrgyógyászati Klinika', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '5000', 'city': 'Szolnok', 'country': 'Hungary', 'facility': 'Allergo-Derm Bakos Kft', 'geoPoint': {'lat': 47.18066, 'lon': 20.19835}}, {'zip': '8900', 'city': 'Zalaegerszeg', 'country': 'Hungary', 'facility': 'Óbudai Egészségügyi Centrum', 'geoPoint': {'lat': 46.83695, 'lon': 16.84401}}, {'zip': 'LV-4501', 'city': 'Balvi', 'country': 'Latvia', 'facility': 'Balvi and Gulbene Hospital Union', 'geoPoint': {'lat': 57.1313, 'lon': 27.26583}}, {'zip': 'LV-1002', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Pauls Stradins Clinical University Hospital', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1004', 'city': 'Riga', 'country': 'Latvia', 'facility': '"LOR" Clinic', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1004', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Children Clinical University Hospital', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1010', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Consilium Medicum', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': '49387', 'city': 'Kaunas', 'country': 'Lithuania', 'facility': 'JSC Ausros Medicinos Centras', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': '08406', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'JSC Inlita', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': 'LT-09109', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Center of Allergy Diagnosis and Treatment', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '30-363', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Centrum Medyczne PLEJADY', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '31-624', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Malopolskie Centrum Alergologii', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-153', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Uniwersytecki Szpital Kliniczny nr 1 w Lodzi', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '20-573', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Doroty Krasowskiej', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '45-401', 'city': 'Opole', 'country': 'Poland', 'facility': 'Uniwersytecki Szpital Kliniczny w Opolu, Pododdział Chorób Wewnętrznych i Alergologii', 'geoPoint': {'lat': 50.67119, 'lon': 17.92604}}, {'zip': '32600', 'city': 'Oświęcim', 'country': 'Poland', 'facility': 'Medicome Sp. z o.o.', 'geoPoint': {'lat': 50.03437, 'lon': 19.21037}}, {'zip': '87-100', 'city': 'Torun', 'country': 'Poland', 'facility': 'Medicover Integrated Clinical Services Sp. zo.o.', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'zip': '02-953', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Klinika Ambroziak sp. z o.o.', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '9324', 'city': 'Bloemfontein', 'state': 'Free State', 'country': 'South Africa', 'facility': 'Iatros International', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}, {'zip': '1500', 'city': 'Benoni', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'WorthWhile Clinical Trials', 'geoPoint': {'lat': -26.18848, 'lon': 28.32078}}, {'zip': '2113', 'city': 'Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Newtown Clinical Research', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '1827', 'city': 'Lenasia', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Ubuntu Clinical Research', 'geoPoint': {'lat': -26.32052, 'lon': 27.83564}}, {'zip': '1935', 'city': 'Vereeniging', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'FCRN Clinical Trial Centre Vaal Triangle', 'geoPoint': {'lat': -26.67313, 'lon': 27.92615}}, {'zip': '4001', 'city': 'Durban', 'state': 'KwaZulu-Natal', 'country': 'South Africa', 'facility': 'Synapta Clinical Research', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '4092', 'city': 'Durban', 'state': 'KwaZulu-Natal', 'country': 'South Africa', 'facility': 'Dr PJ Sebastian', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '7700', 'city': 'Cape Town', 'state': 'Mowbray', 'country': 'South Africa', 'facility': 'The University of Cape Town - Lung Institute', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '03010', 'city': 'Alicante', 'country': 'Spain', 'facility': 'HGU de Alicante', 'geoPoint': {'lat': 38.34517, 'lon': -0.48149}}, {'zip': '8907', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Bellvitge', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '9035', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Vall d´ Hebron', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28027', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Universidad de Navarra', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '29009', 'city': 'Málaga', 'country': 'Spain', 'facility': 'Hospital Regional Universitario de Málaga', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '46015', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Hospital Arnau de Vilanova', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Celldex Therapeutics', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}